BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update.

ENPNewswire-August 5, 2022--BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update

(C)2022 ENPublishing -

Release date- 04082022 - PALO ALTO, CA - BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, reported its financial results for the second quarter ended June 30, 2022, and provided an update on the Company's operations.

'Focused execution is our top priority, and we are delivering with positive proof-of-concept data in three of our key programs so far this year - achondroplasia, ADH1 and LGMD2i. At the same time, we've reported positive data for five additional early-to-mid-stage pipeline programs designed to target a range of genetic diseases with high unmet need. Our productive pipeline is bolstered by new value-creating partnerships, which we believe allow us to keep our attention fixed on driving forward the strongest science for patients,' said Neil Kumar, Ph.D., founder and CEO of BridgeBio.

BridgeBio's Key Programs

Low-dose?infigratinib?- FGFR1-3 inhibitor for achondroplasia and hypochondroplasia

Positive interim results from Phase 2 trial of infigratinib demonstrated a mean increase in annualized height velocity (AHV) of 1.52 cm/year among all children 5 years of age and older enrolled in Cohort 4 (dose: 128 mg/kg once daily) (p=0.02, n=11), the highest dose level evaluated to date based on longest available follow-up at time of data cut

The responder rate was 64% (7 of 11 children) in...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT